Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 6—June 2014

Short-Term Malaria Reduction by Single-Dose Azithromycin during Mass Drug Administration for Trachoma, Tanzania

Stephen E. Schachterle1, George Mtove, Joshua P. Levens, Emily Clemens, Lirong Shi, Amrita Raj, J. Stephen Dumler, Beatriz Munoz, Shelia West, and David J. SullivanComments to Author 
Author affiliations: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (S.E. Schachterle, L. Shi, A. Raj, D.J. Sullivan); National Institute for Medical Research, Ubwari, Tanzania (G. Mtove); Johns Hopkins University School of Medicine, Baltimore (J.P. Levens, E. Clemens, J.S. Dumler, B. Munoz, S. West)

Main Article

Table 2

Univariate association between AZT MDA and Plasmodium falciparum malaria prevalence, Tanzania, January 12–July 21, 2009*

Time No. negative No. positive OR (95% CI)
AZT– 840 54 1.03 (0.68–1.55)
AZT+ 801 53
Month 1
AZT– 742 37 0.34 (0.17–0.64)†
AZT+ 837 14
Month 3
AZT– 653 17 0.83 (0.38–1.77)
AZT+ 700 15
Month 4
AZT– 523 8 0.52 (0.13–1.81)
AZT+ 632 5
Month 6
AZT– 589 4 0.95 (0.18–5.12)
AZT+ 621 4

*AZT, azithromycin; MDA, mass drug administration; OR, odds ratio.

Main Article

1Current affiliation: Pfizer, Inc., New York, New York, USA.

Page created: May 16, 2014
Page updated: May 16, 2014
Page reviewed: May 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.